Protecting Kids from Pneumonia Arlington VA

The current recommended dose schedule for 7-valent pneumococcal conjugate vaccine (PCV-7) consists of three primary doses before the age of 6 months, followed by a booster vaccination in the second year of life (3 + 1-dose schedule) in Arlington.

William George Giasi, MD
(703) 553-4447
Apt 658 2700 16th St S
Arlington, VA
Specialties
Pediatrics
Gender
Male
Education
Graduation Year: 2003

Data Provided by:
Dr. Aimee Michelle Gibson
(304) 388-1563
Arlington, VA
Specialty
Pediatrics

Mikszewski Jerold Md - OFC
(703) 671-5400
611 South Carlin Springs Road
Arlington, VA
 
Arti Jaiswal, MD
(646) 251-0613
1530 Key Blvd Apt 829
Arlington, VA
Specialties
Pediatrics
Gender
Male
Education
Graduation Year: 2003

Data Provided by:
Sharma Ashok K MD
(703) 931-4404
611 South Carlin
Arlington, VA
 
Rebecca Jean Eick, MD
(757) 470-4546
Apt 2 1611 28th St S
Arlington, VA
Specialties
Pediatrics
Gender
Female
Education
Medical School: Univ Of South Fl Coll Of Med, Tampa Fl 33612
Graduation Year: 2002

Data Provided by:
Prostate Care Center
(703) 671-7717
S 611 Carlin Springs Road
Arlington, VA
 
Lucas L Kulczycki, MD, FRCP, FAAP
1507 N Kirkwood Rd
Arlington, VA
Specialties
Pediatrics
Gender
Male
Education
Graduation Year: 1946

Data Provided by:
Aparna Sarin, MD
1111 Arlington Blvd Apt 725
Arlington, VA
Specialties
Pediatrics
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Dr. Noelle Elizabeth Bach Halloin
(314) 753-8223
828 S Irving St
Arlington, VA
Specialty
Pediatrics

Data Provided by:

Protecting Kids from Pneumonia

Provided By:

Parents and babies alike will be relieved by new findings that show a reduced-dose schedule for the pneumococcal vaccine can protect infants against pneumonia and other infections.

The current recommended dose schedule for 7-valent pneumococcal conjugate vaccine (PCV-7) consists of three primary doses before the age of 6 months, followed by a booster vaccination in the second year of life (3 + 1-dose schedule). But factors such as questions about the cost-effectiveness of the current PCV-7 dose schedule have led researchers to examine reduced-dose vaccine schedules, according to background information in the study.

The researchers, Dr. Elske J.M. van Gils, of the University Medical Center Utrecht in the Netherlands, and colleagues, studied 1,003 healthy infants who were randomly assigned to receive two doses of PCV-7 at 2 months and 4 months of age, or a 2 + 1-dose schedule at 2, 4 and 11 months of age, or no vaccine (control group). The children were checked after 12 months, 18 months and 24 months for pneumococcal microorganisms in the upper part of the throat behind the nose.

Compared to those in the control group, children in both vaccine groups had far lower rates of microorganisms that can cause pneumonia and other infections, according to the report in the July 8 issue of the Journal of the American Medical Association.

"In conclusion, both two-dose and 2 + 1-dose schedules of PCV-7 significantly reduce vaccine serotype pneumococcal carriage in children. This study supports future implementation of reduced-dose PCV-7 schedules," the researchers concluded.

More information

The Nemours Foundation has more about children and pneumonia.

SOURCE: Journal of the American Medical Association, news release, July 7, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com